

VOLITIONRX LTD
Form 8-K
November 15, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2016

VolitionRx Limited

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation)

001-36833
(Commission File Number)

91-1949078
(IRS Employer
Identification No.)

1 Scotts Road
#24-05 Shaw Centre
Singapore 228208

Edgar Filing: VOLITIONRX LTD - Form 8-K
(Address of principal executive offices and Zip Code)

+1 (646) 650-1351

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

VOLITIONRX LIMITED

Form 8-K

Current Report

Item 2.02.

Results of Operations and Financial Condition.

The following information, including Exhibits 99.1 and 99.2, is being furnished in accordance with General Instruction B.2. of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act, except as expressly set forth by specific reference in such filing:

As previously announced, on November 10, 2016, VolitionRx Limited hosted a conference call discussing its financial results for the quarter ended September 30, 2016. The conference call was announced by a widely disseminated press release and was made available to the public via audio webcast. Furnished herewith as Exhibits 99.1 and 99.2 and incorporated by reference herein are copies of the press release and a transcript of the conference call, respectively.

Item 9.01.

Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

<u>Number</u>	<u>Description</u>
99.1	Press Release of VolitionRx Limited, dated November 10, 2016.
99.2	Transcript of Conference Call held on November 10, 2016.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 15, 2016

VOLITIONRX LIMITED

By: */s/ Cameron Reynolds*

Cameron Reynolds

Chief Executive Officer & President

EXHIBIT INDEX

Exhibit

<u>Number</u>	<u>Description</u>
99.1	Press Release of VolitionRx Limited, dated November 10, 2016.
99.2	Transcript of Conference Call held on November 10, 2016.